No Data
No Data
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of
Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals
Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne
Buy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical Pipeline
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
Oric Pharmaceuticals Price Target Cut to $14.00/Share From $15.00 by Citigroup
Oric Pharmaceuticals Price Target Cut to $14.00/Share From $15.00 by Citigroup